Scheduled to reviewed by EMA under the centralized marketing authorization procedure, the application, if approved, would eanble the company to market isavuconazole in all 28 European Union member
Located in Wisconsin-Madison University Research Park, the 37,000ft2 sterile injectable fill finish facility will be a newly formed subsidiary of PSC Biotech, and will be named BioTechnique. The
All CCH three doses, including a low, medium and high dose, demonstrated an improvement in the appearance of cellulite as measured by the trial endpoints of physician and
The latest approval will pave for Cbris Lifesciences to improve capacities to develop in the regulated markets, mainly the European Union. By the end of June, Cbris had
As part of the move, hydrocodone combination products (HCP) have now been moved to the more-restrictive Schedule II substances from Schedule III. The new rule will go live
Based on data from the global AMPLIFY and AMPLIFY-EXT studies, Eliquis was also cleared for the reduction in the risk of recurrent DVT and PE following initial therapy.
Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO’s TSR-011.
PGTC is one of the most severe forms of generalized seizures, accounting for approximately 60% of generalized epilepsy and approximately 20% of all epilepsy cases. This application was
Under the agreement, the company has purchased ANDAs for 0.5mg, 1mg and 2mg Estradiol Tablets, and 5mg Selegiline Hydrochloride Capsules. The seller’s identity and the financial terms of
Discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland, GBR 1302 is a HER2xCD3 bispecific antibody based on the company’s BEAT antibody technology
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.